Letter to the Editor Regarding “Perioperative Adjuvant Therapy with Short Course of Dupilumab with ESS for Recurrent CRSwNP”

International Forum of Allergy & Rhinology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

To the Editor: We read with great interest recent randomized controlled trial (RCT) titled "Perioperative Adjuvant Therapy Short Course of Dupilumab ESS for Recurrent CRSwNP" [1]. This innovative study is first RCT to explore perioperative dupilumab usage. The ability biologics such as suppress type 2 inflammation in treating chronic rhinosinusitis nasal polyps (CRSwNP) has been well demonstrated multiple RCTs and subsequent real-world studies [2, 3]. limitations include cost, deterioration disease control when drugs are stopped [2]. Endoscopic sinus surgery (ESS), still considered first-line therapy CRSwNP, limited by polyp recurrence, a reported rate 40% at 18 months [4]. Similar however, recently shown reduce CRSwNP patients 12 after [5]. Exploring potential synergistic effects combining improve outcomes novel approach. believe, that some issues deserve further clarification. First, whether biologic responders have better surgical warrants consideration. authors had good clinical responses (improvement symptoms or smell function) two doses dupilumab. It documented experience favorable response within 1 month Whether being an early responder affects treatment decision-making remains unresolved but important question. interested know versus nonresponders exhibited differential outcomes. presents opportunity begin address this issue, it may suggest who should remain on those proceed surgery. Second, oral corticosteroids widespread use significant negative overall patients' health [6]. would be valuable corticosteroid burden arms, course need steroid rescue treatment. In [1], appears all received 10-day postoperative corticosteroids. As corollary point, obviate well. Moreover, begs question one safer, more effective alternative burst prednisone recurrent exacerbations. usage surgery, research can guide other ENT surgeons toward understanding how impact traditional associated use. value authors' encourage them provide colleagues new insights effectively manage CRSwNP. Robert C. Kern consultant Sanofi, Regeneron, GSK, Lyra Therapeutics.

Language: Английский

---

Biologic Treatments for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): A Comparative Review of Efficiency and Risks

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 22, 2025

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition of the passages and sinuses, often characterized by congestion, loss smell, facial pressure, discharge. Conventional treatments, such as corticosteroids endoscopic sinus surgery (ESS), provide only temporary relief, frequent recurrence symptoms. For patients severe, refractory CRSwNP, biologic therapies have emerged promising treatment option. This review evaluates efficacy safety treatments for including dupilumab, mepolizumab, omalizumab. We analyze clinical trial data, patient-reported outcomes, latest research on use biologics in CRSwNP management. Our findings confirm treating showing consistent improvements both outcomes. The resulted significant reduction polyp size, improved reduced need further or systemic corticosteroids. Moreover, experienced an sense smell better quality life. also includes comparative analysis three biologics, highlighting their efficiency potential risks. suggest that dupilumab may be most effective therapy superior compared to mepolizumab omalizumab reducing size improving congestion. article provides valuable insights healthcare providers considering emphasizing importance personalized decisions based individual patient factors, disease severity, comorbidities, preferences.

Language: Английский

---

Pilot Study on the Efficacy of a Novel Questionnaire for Assessing Psychological Health in Patients with Chronic Rhinosinusitis with Nasal Polyps Treated with Biologics

Healthcare, Journal Year: 2025, Volume and Issue: 13(4), P. 433 - 433

Published: Feb. 18, 2025

Background/Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a debilitating disease significant morbidity and decreased quality of life (QoL). The introduction biologics in its management has allowed new therapeutic options, Dupilumab the first approved biologic. This study aims to evaluate possible relationship between clinical response biological therapy mental health patients severe CRSwNP. Methods: is multicenter conducted at Otolaryngology departments three major Italian institutions. Participants were CRSwNP treated Dupilumab. Patients assessed baseline during treatment by submitting them survey consisting dedicated questionnaire focused on psychological two patient-reported outcome measures (PROMs): 22-item Sino-Nasal Outcome Test (SNOT-22) Visual Analogue Scale (VAS) for symptoms. Results: 86 included (58 males 28 females; mean age: 58.2 years). There was improvement both symptoms QoL, an enhanced state observed after administration within months therapy. Conclusions: evaluated correlations improvements CRSwNP, as through survey, conditions, SNOT-22 VAS. Our findings showed that not only improved but also had positive impact patients' health, benefits already highlights relevance well-being implications chronic diseases such

Language: Английский

---

Secukinumab (Anti‐IL‐17A Therapeutic Antibody) Improves Clinical Outcome for a Mixed Endotype CRS

Clinical Case Reports, Journal Year: 2024, Volume and Issue: 12(12)

Published: Dec. 1, 2024

ABSTRACT We identified two CRSwNP patients who had previously failed treatment with an anti‐IL‐4/IL‐13 antibody (dupilumab). Based on their clinical characteristics and blood cytokine levels, we considered them mixed Type II/Type III cases treated anti‐IL‐17 (secukinumab). Anti‐IL‐17 secukinumab was superior in reducing NPS SNOT‐22 values compared to dupilumab. IL‐17 could be a promising target for non‐type II endotype CRS treatment.

Language: Английский

---